利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

34 条记录 (耗时 0.049 秒)

    Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells
    6.
    发明授权
    Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells 失效
    生产高滴度病毒和高效逆转录病毒介导的哺乳动物细胞转导的方法

    公开(公告)号：US06506604B2

    公开(公告)日：2003-01-14

    申请号：US09944411

    申请日：2001-09-04

    申请人： Mitchell H. Finer ,  Thomas J. Dull ,  Krisztina M. Zsebo ,  Keegan Cooke ,  Deborah A. Farson

    发明人： Mitchell H. Finer ,  Thomas J. Dull ,  Krisztina M. Zsebo ,  Keegan Cooke ,  Deborah A. Farson

    IPC分类号： C12N15867

    CPC分类号： C12N7/00 ,  A61K48/00 ,  C07K14/005 ,  C07K14/7051 ,  C07K14/70514 ,  C07K14/721 ,  C07K16/10 ,  C07K2319/00 ,  C12N15/86 ,  C12N15/87 ,  C12N2740/13022 ,  C12N2740/13043 ,  C12N2740/13052 ,  C12N2740/13062

    摘要： The invention provides a novel retroviral packaging system, in which retroviral packaging plasmids and packagable vector transcripts are produced from high expression plasmids after stable or transient transfection in mammalian cells. High titers of recombinant retrovirus are produced in these transfected mammalian cells and can then transduce a mammalian target cell by cocultivation or supernatant infection. The methods of the invention include the use of the novel retroviral packaging plasmids and vectors to transduce primary human cells, including T cells and, human hematopoietic stem cells, with foreign genes by cocultivation or supernatant infection at high efficiencies. The invention is is useful for the rapid production of high titer viral supernatants, and to transduce with high efficiency cells that are refractory to transduction by conventional means.

    摘要翻译： 本发明提供了一种新型的逆转录病毒包装系统，其中在哺乳动物细胞中稳定或瞬时转染之后，由高表达质粒产生逆转录病毒包装质粒和可包装载体转录物。 在这些转染的哺乳动物细胞中产生高滴度的重组逆转录病毒，然后可以通过共培养或上清液感染来转导哺乳动物靶细胞。 本发明的方法包括使用新的逆转录病毒包装质粒和载体以高效率通过共培养或上清液感染来转导包含T细胞和人造血干细胞的原代人细胞与外来基因。 本发明可用于快速生产高滴度病毒上清液，并且可以通过常规方法转导难以转导的高效细胞。

    Membrane bound stem cell factor therapy for ischemic heart
    8.
    发明授权
    Membrane bound stem cell factor therapy for ischemic heart 有权
    膜结合干细胞因子治疗缺血性心脏

    公开(公告)号：US08404653B2

    公开(公告)日：2013-03-26

    申请号：US12084673

    申请日：2006-11-13

    申请人： Krisztina M. Zsebo

    发明人： Krisztina M. Zsebo

    IPC分类号： A61K48/00 ,  A01N63/00

    CPC分类号： A61K48/005

    摘要： The present invention relates to the use of stem cell factor (SCF) for the treatment of ischemic injured tissue such as in cardiovascular disease. The method involves administration of a nucleic acid encoding SCF, wherein the nucleic acid is delivered to the site of the injury and is incorporated into cells which then express the SCF.

    摘要翻译： 本发明涉及干细胞因子（SCF）用于治疗缺血性损伤组织如心血管疾病的用途。 该方法涉及施用编码SCF的核酸，其中所述核酸被递送到损伤部位，并且被并入然后表达SCF的细胞中。

    Production of antibodies using cre-mediated site-specific recombination
    9.
    发明授权
    Production of antibodies using cre-mediated site-specific recombination 有权

    公开(公告)号：US07145056B2

    公开(公告)日：2006-12-05

    申请号：US10210425

    申请日：2002-07-31

    申请人： Aya Jakobovits ,  Krisztina M. Zsebo

    发明人： Aya Jakobovits ,  Krisztina M. Zsebo

    IPC分类号： A61J67/00 ,  A61J48/00 ,  C12N5/00 ,  C12N15/00 ,  C12N15/63

    CPC分类号： C12N15/90 ,  A01K2207/15 ,  A01K2217/00 ,  A01K2217/05 ,  A01K2217/075 ,  A01K2227/105 ,  A01K2267/01 ,  A01K2267/03 ,  C07K16/00 ,  C12N15/8509 ,  C12N2800/30

    摘要： A method to produce a cell expressing an antibody from a genomic sequence of the cell comprising a modified immunoglobulin locus using Cre-mediated site-specific recombination is disclosed. The method involves first transfecting an antibody-producing cell with a homology-targeting vector comprising a lox site and a targeting sequence homologous to a first DNA sequence adjacent to the region of the immunoglobulin loci of the genomic sequence which is to be converted to a modified region, so the first lox site is inserted into the genomic sequence via site-specific homologous recombination. Then the cell is transfected with a lox-targeting vector comprising a second lox site suitable for Cre-mediated recombination with the integrated lox site and a modifying sequence to convert the region of the immunoglobulin loci to the modified region. This conversion is performed by interacting the lox sites with Cre in vivo, so that the modifying sequence inserts into the genomic sequence via Cre-mediated site-specific recombination of the lox sites. Also disclosed are a form of the method used to produce a cell expressing a modified antibody molecule using Cre-mediated site-specific recombination, and antibody-producing cells obtainable by the disclosed methods. Class-switching modifications of human antibodies produced in murine hybridoma cells are exemplified.